🇺🇸 Protease Inhibitor in United States

86 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 86

Most-reported reactions

1. Anaemia — 15 reports (17.44%)
2. Rash — 11 reports (12.79%)
3. Diarrhoea — 10 reports (11.63%)
4. Pyrexia — 9 reports (10.47%)
5. Nausea — 8 reports (9.3%)
6. Fatigue — 7 reports (8.14%)
7. Pneumonia — 7 reports (8.14%)
8. Thrombocytopenia — 7 reports (8.14%)
9. Haemoglobin Decreased — 6 reports (6.98%)
10. Headache — 6 reports (6.98%)

Source database →

Frequently asked questions

Is Protease Inhibitor approved in United States?

Protease Inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Protease Inhibitor in United States?

Medical Research Council is the originator. The local marketing authorisation holder may differ — check the official source linked above.